Sara Nysom Christiansen, Simon Horskjær Rasmussen, Mikkel Ostergaard, Marion Pons, Brigitte Michelsen, Karel Pavelka, Catalin Codreanu, Adrian Ciurea, Bente Glintborg, Maria Jose Santos, Ismail Sari, Ziga Rotar, Bjorn Gudbjornsson, Gary J Macfarlane, Heikki Relas, Florenzo Iannone, Karin Laas, Johan K Wallman, Marleen van de Sande, Sella Aarrestad Provan, Isabel Castrejon, Jakub Zavada, Corina Mogosan, Michael J Nissen, Anne Gitte Loft, Anabela Barcelos, Yesim Erez, Katja Perdan Pirkmajer, Gerdur Grondal, Gareth T Jones, Anna-Mari Hokkanen, Maria Sole Chimenti, Sigrid Vorobjov, Daniela Di Giuseppe, Tore K Kvien, Lucia Otero-Varela, Irene van der Horst-Bruinsma, Merete Lund Hetland, Lykke Midtbøll Ørnbjerg
{"title":"赛库单抗对放射性和非放射性轴性脊柱关节炎的疗效：一项欧洲常规护理观察研究。","authors":"Sara Nysom Christiansen, Simon Horskjær Rasmussen, Mikkel Ostergaard, Marion Pons, Brigitte Michelsen, Karel Pavelka, Catalin Codreanu, Adrian Ciurea, Bente Glintborg, Maria Jose Santos, Ismail Sari, Ziga Rotar, Bjorn Gudbjornsson, Gary J Macfarlane, Heikki Relas, Florenzo Iannone, Karin Laas, Johan K Wallman, Marleen van de Sande, Sella Aarrestad Provan, Isabel Castrejon, Jakub Zavada, Corina Mogosan, Michael J Nissen, Anne Gitte Loft, Anabela Barcelos, Yesim Erez, Katja Perdan Pirkmajer, Gerdur Grondal, Gareth T Jones, Anna-Mari Hokkanen, Maria Sole Chimenti, Sigrid Vorobjov, Daniela Di Giuseppe, Tore K Kvien, Lucia Otero-Varela, Irene van der Horst-Bruinsma, Merete Lund Hetland, Lykke Midtbøll Ørnbjerg","doi":"10.1136/rmdopen-2024-004166","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe.</p><p><strong>Methods: </strong>Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0-10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated.Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/adjusted for multiple confounders).</p><p><strong>Results: </strong>Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar.During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%).However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates.</p><p><strong>Conclusion: </strong>Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"10 3","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284936/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study.\",\"authors\":\"Sara Nysom Christiansen, Simon Horskjær Rasmussen, Mikkel Ostergaard, Marion Pons, Brigitte Michelsen, Karel Pavelka, Catalin Codreanu, Adrian Ciurea, Bente Glintborg, Maria Jose Santos, Ismail Sari, Ziga Rotar, Bjorn Gudbjornsson, Gary J Macfarlane, Heikki Relas, Florenzo Iannone, Karin Laas, Johan K Wallman, Marleen van de Sande, Sella Aarrestad Provan, Isabel Castrejon, Jakub Zavada, Corina Mogosan, Michael J Nissen, Anne Gitte Loft, Anabela Barcelos, Yesim Erez, Katja Perdan Pirkmajer, Gerdur Grondal, Gareth T Jones, Anna-Mari Hokkanen, Maria Sole Chimenti, Sigrid Vorobjov, Daniela Di Giuseppe, Tore K Kvien, Lucia Otero-Varela, Irene van der Horst-Bruinsma, Merete Lund Hetland, Lykke Midtbøll Ørnbjerg\",\"doi\":\"10.1136/rmdopen-2024-004166\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe.</p><p><strong>Methods: </strong>Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0-10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated.Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/adjusted for multiple confounders).</p><p><strong>Results: </strong>Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar.During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%).However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates.</p><p><strong>Conclusion: </strong>Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.</p>\",\"PeriodicalId\":21396,\"journal\":{\"name\":\"RMD Open\",\"volume\":\"10 3\",\"pages\":\"\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2024-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284936/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"RMD Open\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/rmdopen-2024-004166\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"RMD Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/rmdopen-2024-004166","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study.
Objectives: To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe.
Methods: Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0-10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated.Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/adjusted for multiple confounders).
Results: Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar.During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%).However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates.
Conclusion: Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.
期刊介绍：
RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
